ABBOTT LABORATORIESABT
ASignal's systematic analysis rates ABT as Neutral.
Reflects the latest available analysis · analyzed Oct 28, 2026
The case on ABT
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Positive MACD histogram indicating strengthening momentum
- Price above 20-day and 50-day moving averages
- Strong gross margin of 57.08% indicating pricing power
- Revenue growth of 14.5% YoY in medical devices sector
- Debt-to-equity ratio of 0.63x, within moderate range
- Dividend yield of 2.52% with sustainable payout ratio
- RSI at 63.99, approaching overbought territory
- Negative year-over-year earnings growth (-43.7%)
- Missing key fundamental metrics: ROE, ROA, current ratio, free cash flow
- Forward P/E of 17.37x above sector median, raising valuation concerns
- No Reddit mentions, indicating low retail investor interest
Peers
Clustered with ABT by analysis-profile similarity.
See the full verdict on ABT
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes ABT
Most investors never get a second opinion, let alone several. ASignal runs ABT past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.